Transcreener™: Screening enzymes involved in covalent regulation

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 1, 2006, Pages 179-190

  Lowery, Robert G ^a   Kleman Leyer, Karen ^a  

^a BellBrook Labs   (United States)

Author keywords

Covalent modification; Fluorescence polarisation; Glycosylation; Glycosyltransferase; High throughput screening (HTS); Phosphorylation; Protein kinase; Sulfation; Sulfonation; Sulfotransferase

Indexed keywords

ACYLTRANSFERASE; ENZYME; GLYCOSYLTRANSFERASE; ISOENZYME; METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOTIDE; PROTEIN KINASE; PROTEOME; REAGENT; SULFOTRANSFERASE; ENZYME INHIBITOR;

ACETYLATION; ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; CHEMICAL REACTION; DEVICE; DRUG TARGETING; ENZYME SUBSTRATE; FLUORESCENCE; GLYCOSYLATION; HIGH THROUGHPUT SCREENING; HUMAN; METHYLATION; PHOSPHORYLATION; REGULATORY MECHANISM; SCREENING; SULFONATION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; ENZYME SPECIFICITY; FLUORESCENCE POLARIZATION; INSTRUMENTATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYMES; FLUORESCENCE POLARIZATION; HUMANS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 33144487285     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.1.179     Document Type: Article

References (73)

1. SEO J, LEE KJ: Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J. Biochem. Mol. Biol. (2004) 37(1):35-44.
2. YANG XJ: Multisite protein modification and intramolecular signaling. Oncogene (2005) 24(10):1653-1662.
3. COHEN P: The regulation of protein function by multisite phosphorylation-a 25 year up date. Trends Biochem. Sci. (2000) 25(12):596-601.
4. SPIRO RG: Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology (2002) 12(4):43R-56R.
5. KOUZARIDES T: Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. (2002) 12(2):198-209.
6. WORM J, GULDBERG P: DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J. Oral Pathol. Med. (2002) 31(8):443-449.
7. STROTT CA: Sulfonation and molecular action. Endocr. Rev. (2002) 23(5):703-732.
8. TUKEY RH, STRASSBURG CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Ann. Rev. Pharmacol. Toxicol. (2000) 40:581-616.
9. XIE L, BOURNE PE: Functional coverage of the human genome by existing structures, structural genomics targets, and homology models. PLoS Comput. Biol. (2005) 1(3):e31.
10. GOLDBETER A, KOSHLAND DE, JR.: An amplified sensitivity arising from covalent modification in biological systems. Proc. Natl. Acad. Sci. USA (1981) 78(11):6840-6844.
11. COHEN P: Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. (2002) 1(4):309-315.
12. HEMMERICH S, VERDUGO D, RATH VL: Strategies for drug discovery by targeting sulfation pathways. Drug Discov. Today (2004) 9(22):967-975.
13. DUBE DH, BERTOZZI CR: Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. (2005) 4(6):477-488.
14. KOSTICH M, ENGLISH J, MADISON V et al.: Human members of the eukaryotic protein kinase family. Genome Biol. (2002) 3(9):Research0043.1-0043.12.
15. HANKS SK: Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. (2003) 4(5):111.
16. MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
17. SRIDHAR R, HANSON-PAINTON O, COOPER DR: Protein kinases as therapeutic targets. Pharm. Res. (2000) 17(11):1345-1353.
18. DANCEY J, SAUSVILLE EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. (2003) 2(4):296-313.
19. ROSS H, ARMSTRONG CG, COHEN P: A non-radioactive method for the assay of many serine/threonine-specific protein kinases. Biochem. J. (2002) 366(Pt 3):977-981.
20. SILLS MA, WEISS D, PHAM Q, SCHWEITZER R, WU X, WU JJ: Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J. Biomol. Screen (2002) 7(3):191-214.
21. KIANG TK, ENSOM MH, CHANG TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. (2005) 106(1):97-132.
22. DWEK MV, BROOKS SA: Harnessing changes in cellular glycosylation in new cancer treatment strategies. Curr. Cancer Drug Targets (2004) 4(5):425-442.
23. FUSTER MM, ESKO JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer (2005) 5(7):526-542.
24. BUTTERS TD, MELLOR HR, NARITA K, DWEK RA, PLATT FM: Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2003) 358(1433):927-945.
25. HU Y, HELM JS, CHEN L et al.: Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem. Biol. (2004) 11(5):703-711.
26. ZAWADZKE LE, WU P, COOK L et al.: Targeting the MraY and MurG bacterial enzymes for antimicrobial therapeutic intervention. Anal. Biochem. (2003) 314(2):243-252.
27. BATT AM, MAGDALOU J, VINCENT-VIRY M et al.: Drug metabolizing enzymes related to laboratory medicine: cytochromes P450 and UDP-glucuronosyltransferases. Clin. Chim. Acta. (1994) 226(2):171-190.
28. TRUBETSKOY OV, SHAW PM: A fluorescent assay amenable to measuring production of beta-D-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Drug Metab. Dispos. (1999) 27(5):555-557.
29. ADAMIA S, MAXWELL CA, PILARSKI LM: Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2005) 5(1):3-14.
30. SIMPSON MA, WILSON CM, MCCARTHY JB: Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. (2002) 161(3):849-857.
31. YABUSHITA H, NOGUCHI M, KISHIDA T et al.: Hyaluronan synthase expression in ovarian cancer. Oncol. Rep. (2004) 12(4):739-743.
32. GUO HB, LEE I, KAMAR M, AKIYAMA SK, PIERCE M: Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Res. (2002) 62(23):6837-6845.
33. DENG C, CHEN RR: A pH-sensitive assay for galactosyltransferase. Anal. Biochem. (2004) 330(2):219-226.
34. HANG HC, YU C, PRATT MR, BERTOZZI CR: Probing glycosyltransferase activities with the Staudinger ligation. J. Am. Chem. Soc. (2004) 126(1):6-7.
35. FALANY CN: Enzymology of human cytosolic sulfotransferases. FASEB J. (1997) 11(4):206-216.
36. PARKINSON A: Biotransformation of Xenobiotics. Casaret & Doull's Toxicology Sixth Edition (2001):133-224.
37. GLATT H: Sulfotransferases in the bioactivation of xenobiotics, Chem. Biol. Interact. (2000) 129(1-2):141-170.
38. COUGHTRIE MW, JOHNSTON LE: Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance. Drug Metab. Dispos. (2001) 29(4 Pt 2):522-528.
39. XU W. CHEN H, DU K et al.: A transcriptional switch mediated by cofactor methylation. Science (2001) 294(5551):2507-2511.
40. ADJEI AA, THOMAE BA, PRONDZINSKI JI, ECKLOFF BW, WIEBEN ED, WEINSHILBOUM RM: Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br. J. Pharmacol. (2003) 139(8):1373-1382.
41. FREIMUTH RR, ECKLOFF B, WIEBEN ED, WEINSHILBOUM RM: Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. Pharmacogenetics (2001) 11(9):747-756.
42. THOMAE BA, ECKLOFF BW, FREIMUTH RR, WIEBEN ED, WEINSHILBOUM RM: Human sulfontransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J. (2002) 2(1):48-56.
43. THOMAE BA, RIFKI OF, THEOBALD MA, ECKLOFF BW, WIEBEN ED, WEINSHILBOUM RM: Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism, J. Neurochem. (2003) 87(4):809-819.
44. CARLINI EJ, RAFTOGIANIS RB, WOOD TC et al: Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics (2001) 11(1):57-68.
45. NOWELL S, SWEENEY C, WINTERS M et al.: Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl. Cancer Inst. (2002) 94(21):1635-1640.
46. CHETRITE GS, PASQUALINI JR: The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem. Mol. Biol. (2001) 76(1-5):95-104.
47. ADJEI AA, WEINSHILBOUM RM: Catecholestrogen sulfation: possible role in carcinogenesis. Biochem. Biophys. Res. Commun. (2002) 292(2):402-408.
48. MERTEN M, DONG JF, LOPEZ JA, THIAGARAJAN P: Cholesterol sulfate: a new adhesive molecule for platelets. Circulation (2001) 103(16):2032-2034.
49. ZHU X, SONG J, MAR MH, EDWARDS LJ, ZEISEL SH: Phosphatidylethanolamine N-methyltransferase (PEMT) knockout mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochem. J. (2003) 370(Pt 3):987-993.
50. PLASSART-SCHIESS E, BAULIEU EE: Neurosteroids: recent findings. Brain Res. Brain Res. Rev. (2001) 37(1-3):133-140.
51. STROTT CA; Steroid sulfotransferases. Endocr. Rev. (1996) 17(6):670-697.
52. RAFTOGIANIS R, CREVELING C, WEINSHILBOUM R, WEISZ J: Estrogen metabolism by conjugation. J. Natl. Cancer Inst. Monogr. (2000) 27:113-124.
53. ZAMAN GJ, GARRITSEN A, DE BOER T, VAN BOECKEL CA. Fluorescence assays for high-throughput screening of protein kinases. Comb. Chem High Throughput Screen (2003) 6(4):313-320.
54. GAUDET EA, HUANG KS, ZHANG Y, HUANG W, MARK D, SPORTSMAN JR. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J. Biomol. Screen (2003) 8(2):164-175.
55. FOWLER A, SWIFT D, LONGMAN E et al.: An evaluation of fluorescence polarization and lifetime discriminated polarization for high throughput screening of serine/threonine kinases. Anal. Biochem. (2002) 308(2):223-231.
56. XU K, STERN AS, LEVIN W, CHUA A. VASSILEV LT: A generic time-resolved fluorescence assay for serine/threonine kinase activity: application to Cdc7/Dbf4. J. Biochem. Mol. Biol. (2003) 36(4):421-425.
57. EGLEN RM, SINGH R. Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening. Comb. Chem. High Throughput Screen (2003) 6(4):381-387.
58. XUE Q, WAINRIGHT A, GANGAKHEDKAR S, GIBBONS I: Multiplexed enzyme assays in capillary clectrophoretic single-use microfluidic device. Electrophoresis (2001) 22(18):4000-4007.
59. KORESAWA M, OKABE T: High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. (2004) 2(2):153-160.
60. WALTERS WP, NAMCHUK M: Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov. (2003) 2(4):259-266.
61. CHECOVICH WJ, BOLGER RE, BURKE T: Fluorescence polarization-a new tool for cell and molecular biology. Nature (1995) 375(6528):254-256.
62. OWICKI JC: Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J. Biomol. Screen (2000) 5(5):297-306.
63. SEETHALA R. Fluorescence polarization competition immunoassay for tyrosine kinases. Methods (2000) 22(1):61-70.
64. PARKER GJ, LAW TL, LENOCH FJ, BOLGER RE: Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J. Biomol. Screen (2000) 5(2):77-88.
65. STRAHL BD, BRIGGS SD, BRAME CJ et al.: Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr. Biol. (2001) 11(12):996-1000.
66. OBACH RS, BAXTER JG, LISTON TE et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. (1997) 283(1):46-58.
67. WEINSHILBOUM R: Inheritance and drug response. N. Engl. J. Med. (2003) 348(6):529-537.
68. SEVERINO G, CHILLOTTI C, STOCHINO ME, DEL ZOMPO M: Pharmacogenomics: state of the research and perspectives in clinical application. Neurol. Sci. (2003) 24(Suppl. 2):S146-S148.
69. MURPHY MP: Pharmacogenomics: a critical component of patient stratification during drug development. Expert Rev. Mol. Diagn. (2002) 2(1):1-4.
70. SCHRAG A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol. (2005) 4(6):366-370.
71. CHOU TY, HART GW: O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv. Exp. Med. Biol. (2001) 491:413-418.
72. GRANOVSKY M, FATA J, PAWLING J, MULLER WJ, KHOKHA R, DENNIS JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. (2000) 6(3):306-312.
73. SEIDENFADEN R, KRAUTER A, SCHERTZINGER F, GERARDY-SCHAHN R, HILDEBRANDT H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. Mol. Cell Biol. (2003) 23(16):5908-5918.